Cone damage in patients receiving high-dose irofulven treatment

Archives of Ophthalmology

Volumn 123, Issue 1, 2005, Pages 29-34

  Lee, Michael S ^a   Gupta, Nisha ^b   Penson, Richard T ^c   Loewenstein, John ^d   Wepner, Meredith S ^b   Seiden, Michael V ^c   Milam, Ann H ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; CARBOPLATIN; IROFULVEN; SESQUITERPENE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MEGADOSE; ELECTRORETINOGRAM; FEMALE; HUMAN; IMMUNOCHEMISTRY; MUELLER CELL; OPHTHALMOLOGY; OVARY CANCER; PERIMETRY; PHASE 2 CLINICAL TRIAL; PHOTORECEPTOR; PRIORITY JOURNAL; RETINA CONE; RETINA INJURY; VISUAL FIELD;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CONES (RETINA); ELECTRORETINOGRAPHY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MIDDLE AGED; NEOPLASMS; PERIMETRY; RETINAL DISEASES; RHODOPSIN; SESQUITERPENES; VISUAL FIELDS;

EID: 12144266338     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.1.29     Document Type: Article

References (22)

1. Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3:1683-1689.
2. Vizel M, Oster MW. Ocular side effects of cancer chemotherapy. Cancer. 1982;49:1999-2002.
3. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 1989;34:209-230.
4. Pippitt CH, Muss HB, Homesley HD, et al. Cisplatin-associated cortical blindness. Gynecol Oncol. 1981;12:253-255.
5. Cattaneo MT, Filipazzi V, Piazza E, Damiani E, Mancarella G. Transient blindness and seizure associated with cisplatin therapy. J Cancer Res Clin Oncol 1988;114:528-530.
6. O'Brien ME, Tonge K, Blake P, Moskovic E, Wiltsnaw E. Blindness associated with high-dose carboplatin. Lancet 1992;339:558.
7. Rankin EM, Pitts JF. Ophthalmic toxicity during carboplatin therapy. Ann Oncol. 1993;4:337-338.
8. Capri G, Munzone E, Tarenzi E, et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst. 1994;86:1099-2001.
9. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995;13:2575-2581.
10. Hofstra LS, de Vries EG, Willemse PH. Ophthalmic toxicity following paclitaxel infusion. Ann Oncol. 1997;8:1053.
11. Tan WW, Walsh T. Ocular toxicity secondary to paclitaxel in two lung cancer patients. Med Pediatr Oncol. 1998;31:177.
12. Woynarowski JM, Napier C, Koester S, et al. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol. 1997;54:1181-1193.
13. MacDonald JR, Muscoplat CC, Dexter DL, et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res. 1997;57:279-283.
14. Alexandre J, Kahatt C, Ould Kaci M, et al. Phase I study of irofulven (mgi 114) given as a 5′ infusion once every 2 weeks: preliminary results [abstract]. Proc Am Soc Clin Oncol. 2001;20:83b No. 2083.
15. Milam AH. Immunocytochemical studies of the retina. Methods Mol Med. 2000;47:71-88.
16. Melendez RF, Harrison JM, Rowinsky EK, et al. Acute retinal toxicity from a novel anti-tumor agent, MGI-114 [ARVO abstract]. Invest Ophthalmol Vis Sci. 2003; 44:e-abstract 4927. Available at: http://www.iovs.org. Accessed February 12, 2004.
17. Milam AH, Li ZY, Fariss RN. Histopathology of the human retina in retinitis pigmentosa. Prog Retin Eye Res. 1998;17:175-205.
18. Katz BJ, Ward JH, Digre KB, et al. Persistent severe visual and electroretinographic abnormalities after intravenous cisplatin therapy. J Neuroophthalmol. 2003;23:132-135.
19. Heckenlively JR, Fawzi AA, Oversier J, Jordan BL, Aptsiauri N. Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthalmol. 2000;118:1525-1533.
20. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34:91-100.
21. Cogan DG, Kuwabara T, Currie J, Kattah J. Paraneoplastische Retinopathie unter dem klinischen Bild einer Zapfendystrophie mit Achromatopsie. Klin Monatsbl Augenheilkd. 1990;197:156-158.
22. Jacobson DM, Thirkill CE. Paraneoplastic cone dysfunction: an unusual visual remote effect of cancer. Arch Ophthalmol. 1995;113:1580-1582.